百奥泰:乌司奴单抗注射液获欧洲药品管理局人用药品委员会积极意见

智通财经
20 Jun

智通财经APP讯,百奥泰(688177.SH)公告,公司近日收到了欧洲药品管理局(简称“EMA”)的通知,Usymro®(BAT2206,乌司奴单抗注射液)获得EMA人用药品委员会(简称“CHMP”)积极意见。CHMP建议欧盟委员会(EC)批准Usymro®上市,用于治疗成人及儿童的:中重度斑块状银屑病(PsO),活动性银屑病关节炎(PsA),中重度活动性克罗恩病(CD)。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10